Ouro Fino Saúde Animal Participações Valuation

Q: What is the Fair Price of OFSA3 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

OFSA3 (R$22.62) is trading above our estimate of [[fair value]] (R$10.81)

Is OFSA3 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of OFSA3 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: OFSA3 (R$22.62) is trading above our estimate of fair value (R$10.81)

Significantly Below Fair Value: OFSA3 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for OFSA3?

Key metric: As OFSA3 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for OFSA3. This is calculated by dividing OFSA3's market cap by their current earnings.
What is OFSA3's PE Ratio?
PE Ratio	13.4x
Earnings	R$91.06m
Market Cap	R$1.22b

OFSA3 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.4x
Enterprise Value/EBITDA	8x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does OFSA3's PE Ratio compare to its peers?

The above table shows the PE ratio for OFSA3 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	12.1x
HYPE3 Hypera	8.1x	13.9%	R$12.7b
BLAU3 Blau Farmacêutica	14x	18.2%	R$2.7b
4577 Daito PharmaceuticalLtd	10.2x	8.8%	JP¥32.8b
A216080 JETEMA	16x	35.3%	₩322.8b
OFSA3 Ouro Fino Saúde Animal Participações	13.4x	n/a	R$1.2b

Price-To-Earnings vs Peers: OFSA3 is expensive based on its Price-To-Earnings Ratio (13.4x) compared to the peer average (12.1x).

Price to Earnings Ratio vs Industry

How does OFSA3's PE Ratio compare vs other companies in the Global Pharmaceuticals Industry?

25 Companies	Price / Earnings	Estimated Growth	Market Cap

25 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: OFSA3 is good value based on its Price-To-Earnings Ratio (13.4x) compared to the Global Pharmaceuticals industry average (23.1x).

Price to Earnings Ratio vs Fair Ratio

What is OFSA3's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

OFSA3 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	13.4x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate OFSA3's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Novartis

CHF 187.3b

Engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally.

N1VS34

CHF 60.90

0.8%

26.5%

Blau Farmacêutica

R$2.7b

A pharmaceutical company provides high-complpexity drugs in Brazil, Argentina, Chile, Colombia, Uruguay, Ecuador, Peru, and the United States.

BLAU3

R$14.70

-1.5%

-8.4%

BeiGene

US$20.2b

An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.

B1GN34

US$45.36

n/a